Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has been granted a new Australian Patent by IP Australia's Patent Office titled Pharmaceutical Compositions for Buccal and Pulmonary Application. The patent covers claims to the composition, processes, and methodologies for the delivery of macromolecules via the buccal cavity of the mouth.

The patent, an extant United States Patent held by the company, relates to an improved pharmaceutical composition comprising macromolecule pharmaceuticals in micellar form which are particularly effective in buccal and pulmonary applications. The invention relates to methods for preparing and using these pharmaceutical compositions. Methods for enhancing the rate of absorption of a macromolecular pharmaceutical agent are also disclosed, a Generex Bio release stated.

The company currently holds an aggregate of 79 patents worldwide (20 of which are United States Patents) and has an aggregate of 61 patent applications pending in various jurisdictions.